BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Ares-Serono (Europe) Ltd, submitted on 27 June 1996 to the European Agency for the 
Evaluation  of  Medicinal  Products  (EMEA),  an  application  to  obtain  marketing  authorisation  for  the 
medicinal product Rebif, in accordance with the Centralised procedure falling within the scope of Part 
A of the Annex to Council Regulation No. (EC) 2309/93 of 22 July 1993.  
The CPMP confirmed the status of the Rapporteur and Co-Rapporteur as follows: 
Rapporteur: 
Dr. P. Sjöberg 
Co-Rapporteur:  Dr. M. Marselos 
Licensing status: 
A  new  drug  application  was  pending  in  the  following  countries  at  the  time  of  submission  of  the 
application: 
Switzerland, Norway, Iceland, Canada 
The  product  was  licensed  in  countries  inside  and  outside  the  EU  at  the  time  of  submission  of  the 
application: 
(For different indications) 
Italy (27.4.93), Argentina (4.7.94), Hong Kong (8.2.96) 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The Rapporteur's initial assessment report was circulated to all CPMP Members on 
27 September 1996. The Co-Rapporteur's initial assessment report was circulated to all CPMP 
Members on 27 September 1996. 
During  the  meeting  on  19  November  1996  the  CPMP  agreed  on  the  consolidated  list  of 
questions to be sent to the company on 21 November 1996. 
The final consolidated list of questions was sent to the Company on 21 November 1996. 
The company submitted the responses to the consolidated list of questions on 26 May and on  
10 July 1997. 
The Rapporteur circulated the comments on the company’s responses to the list of questions to 
all CPMP Members on 26 August 1997. 
The Biopharmaceutical part of the dossier was discussed at the Biotechnology  Working Party 
meeting on 7 September 1997. 
The  CPMP,  during  its  meeting  on  22-24  September  1997  discussed  the  recommendations 
presented by the Rapporteurs, considering the medicinal product approvable but the responses 
provided  by  the  company  not  to  be  fully  satisfactory.  A  list  of  additional  information  to  be 
provided  by  the  company  was  agreed  and  the  need  for  an  oral  explanation  discussed  and  in 
principle agreed. 
The  CPMP,  during  its  meeting  on  22-24  September  1997  agreed  on  the  conduct  of  a  Good 
Clinical Practice compliance verification of the main clinical trial. 
A second CPMP list of points for clarification was sent to the Applicant on 25 September 1997. 
The company provided additional information on 10 November 1997. 
The  Rapporteurs’  assessment  of  the  additional  information  provided  by  the  Applicant  was 
circulated on 8 December 1997. 
During the Biotechnology Working Party meeting held on 9-10 December 1997 the remaining 
points  were  discussed  and  from  the  quality  stand  point  a  positive  recommendation  for  the 
granting of a marketing authorisation was adopted. 
1/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
• 
• 
• 
The  CPMP,  during  its  meeting  on  15-17  December  1997  discussed  the  recommendations 
presented  by  the  Rapporteur,  considering  the  responses  provided  by  the  company  were 
satisfactory.  Amendments  were  discussed  to  the  Summary  of  Product  Characteristics.  The 
Package Leaflet text was amended accordingly. 
The  CPMP  during  its  meeting  on  15-17  December  1997,  in  the  light  of  the  current  scientific 
standards  recommended  the  granting  of  a  Marketing  Authorisation  under  exceptional 
circumstances, in accordance with Article 13 (2) of Council Regulation (EEC) No 2309/93 and 
Part 4 G of the annex to Council Directive 75/318/EEC Rebif. 
The  CPMP  with  reference  to  Part  4  G  of  the  annex  to  Council  Directive  75/318/EEC, 
considered that in the present state of scientific knowledge, comprehensive information on the 
safety and efficacy of the medicinal product cannot be provided by the applicant. 
2/2 
EMEA 2005 
 
 
 
 
 
